跳至主要内容
临床试验/NCT06488274
NCT06488274招募中不适用

Assessment of the Evolution of functIonal Gastrointestinal Disorders in Infants During Their Dietary Management With a New Infant Formula

United Pharmaceuticals4 个研究点 分布在 1 个国家目标入组 139 人开始时间: 2024年10月21日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
入组人数
139
试验地点
4
主要终点
Change from baseline of the Gastrointestinal and Gastroesophageal Reflux (GIGER) scale score

研究概览

简要总结

This study aims to assess the evolution of functional gastrointestinal disorders (FGIDs) in infants fed with a new infant formula, using the Gastrointestinal (GI) and gastroesophageal reflux (GER) (GIGER) scale through an interventional, open-label, non-comparative multicenter study.

详细描述

The study comprises a first period of 30 days followed by an optional intervention period of 90 days.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Other
盲法
None

入排标准

年龄范围
— 至 4 Months(Child)
性别
All
接受健康志愿者

入选标准

  • Infants presenting with at least one of the FGIDs below, defined based on adapted Rome IV criteria as follows:
  • 1.1 Regurgitations: 1.2 Colic: 1.3 Constipation:
  • Infants born at 35 weeks or more of gestational age
  • Infants up to 4 months of age

排除标准

  • Exclusively or partially breastfed infants (i.e. > 2 breast feeds per day) with maternal willingness to continue breastfeeding
  • Diversified infants or whose parents intend to start diversification within the first 2 weeks of the study
  • Use of antibiotics at inclusion visit (V0) and within 7 days before the inclusion visit (V0)
  • The willingness to take additional pre-, probiotics or thickening agents during the study
  • Known allergy/intolerance to any of the product ingredients or suspected allergy to cow's milk requiring an eviction diet
  • Infants presenting with any other situation including the participation in another clinical trial, which, according to the investigator, may interfere with the study participation, or lead to a particular risk for the patient
  • (non exhaustive list)

结局指标

主要结局

Change from baseline of the Gastrointestinal and Gastroesophageal Reflux (GIGER) scale score

时间窗: Day 30

The main outcome will be the evolution of the sum score of the Gastrointestinal and Gastroesophageal Reflux (GIGER) scale (Pados et al., 2021). The GIGER score varies from 0 to 180 being the worst.

次要结局

  • Regurgitation severity(Day 14, Day 30, Day 60, Day 90, Day 120)
  • Investigator's evaluation of the evolution of FGIDs(Day 14, Day 30, Day 60, Day 90, Day 120)
  • Height(Day 30, Day 60, Day 90, Day 120)
  • Stool frequency and consistency in non constipated infant(Day 7, Day 14, Day 30, Day 60, Day 90, Day 120)
  • Stool frequency and consistency in constipated infant(Day 7, Day 14, Day 30, Day 60, Day 90, Day 120)
  • Colic(Day 7, Day 14, Day 30, Day 60, Day 90, Day 120)
  • Abdominal distension severity(Day 7, Day 14, Day 30, Day 60, Day 90, Day 120)
  • GIGER score(Day 7, Day 14, Day 60, Day 90, Day 120)
  • Number of bottles at night(D7, D14, D30, D60, D90, D120)
  • Parents' satisfaction(Day 7, Day 14, Day 30, Day 60, Day 90, Day 120)
  • Regurgitation frequency(Day 7, Day 14, Day 30, Day 60, Day 90, Day 120)
  • Weight(Day 30, Day 60, Day 90, Day 120)
  • Gas/flatulence severity(Day 7, Day 14, Day 30, Day 60, Day 90, Day 120)
  • BMI(Day 30, Day 60, Day 90, Day 120)
  • Evolution of FGIDs (regurgitations, colic and constipation)(Day 14, Day 30, Day 60, Day 90, Day 120)
  • Defecation pain frequency in constipated infant(Day 7, Day 14, Day 30, Day 60, Day 90, Day 120)
  • Infant's quality of life(Day 7, Day 14, Day 30, Day 60, Day 90, Day 120)
  • Adverse events(Through study completion (up to 30 days or 120 days if participation to the optional intervention period))
  • Sleep(Day 7, Day 14, Day 30, Day 60, Day 90, Day 120)
  • Head circumference(Day 30, Day 60, Day 90, Day 120)

研究者

申办方类型
Industry
责任方
Sponsor

研究点 (4)

Loading locations...

相似试验